Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Nucleic Acid Amplification Testing Market

ID: MRFR/HC/41467-HCR
200 Pages
Satyendra Maurya, Garvit Vyas
Last Updated: May 15, 2026
Nucleic Acid Amplification Testing Market Research Report: Size, Share, Trend Analysis By Technology (PCR, LAMP, NASBA, RT-PCR), By Applications (Infectious Disease Testing, Cancer Diagnosis, Genetic Testing, Transplant Diagnostics), By End Use (Hospitals, Diagnostic Laboratories, Research Institutes, Home Care Settings), By Product Type (Reagents, Instruments, Software, Consumables) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Nucleic Acid Amplification Testing Market Infographic
Summary Table of Contents Segmentation Methodology Download PDF

Nucleic Acid Amplification Testing Market Summary

As per Market Research Future analysis, the Nucleic Acid Amplification Testing Market was estimated at 7.294 USD Billion in 2024. The Nucleic Acid Amplification Testing industry is projected to grow from 7.964 USD Billion in 2025 to 19.19 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.19% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Nucleic Acid Amplification Testing Market is poised for substantial growth driven by technological advancements and increasing demand for rapid diagnostics.

  • Technological advancements are enhancing the accuracy and efficiency of nucleic acid amplification tests, particularly in North America.
  • Point-of-care testing is gaining traction, especially in the Asia-Pacific region, due to its convenience and rapid results.
  • The PCR segment remains the largest in the market, while RT-PCR is emerging as the fastest-growing segment, reflecting evolving testing needs.
  • Rising prevalence of infectious diseases and increased investment in research and development are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 7.294 (USD Billion)
2035 Market Size 19.19 (USD Billion)
CAGR (2025 - 2035) 9.19%

Major Players

Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Qiagen (DE), Hologic (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Cepheid (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Nucleic Acid Amplification Testing Market Trends

The Nucleic Acid Amplification Testing Market is currently experiencing a notable evolution, driven by advancements in technology and increasing demand for rapid diagnostic solutions. This market encompasses various techniques that amplify nucleic acids, enabling the detection of pathogens and genetic material with high sensitivity and specificity. As healthcare systems worldwide prioritize early diagnosis and personalized medicine, the relevance of nucleic acid amplification tests continues to grow. Furthermore, the integration of automation and artificial intelligence into testing processes appears to enhance efficiency and accuracy, potentially transforming laboratory automation workflows.

In addition to technological advancements, the nucleic acid amplification testing market is influenced by regulatory changes and the need for compliance with stringent quality standards. The emergence of point-of-care testing solutions is also noteworthy, as these innovations facilitate immediate results, thereby improving patient outcomes. As the market evolves, collaboration among stakeholders, including manufacturers, healthcare providers, and regulatory bodies, seems essential for fostering innovation and ensuring the accessibility of these critical diagnostic tools. Overall, the nucleic acid amplification testing market size is poised for continued growth, reflecting the ongoing commitment to enhancing healthcare delivery and disease management strategies.

Technological Advancements

Recent innovations in nucleic acid amplification technologies are reshaping the landscape of diagnostics. Enhanced sensitivity and specificity in testing methods are becoming increasingly prevalent, allowing for more accurate detection of various pathogens. This trend indicates a shift towards more reliable and efficient diagnostic solutions.

Point-of-Care Testing

The rise of point-of-care testing solutions is transforming the nucleic acid amplification testing market  These tests provide immediate results, which can significantly improve patient management and treatment decisions. This trend suggests a growing preference for rapid diagnostics in clinical settings.

Regulatory Compliance and Quality Standards

As the Nucleic Acid Amplification Testing Market expands, adherence to regulatory requirements and quality standards is becoming more critical. This trend highlights the importance of ensuring that testing methods meet stringent guidelines, thereby enhancing the credibility and reliability of diagnostic results.

Nucleic Acid Amplification Testing Market Drivers

Regulatory Support and Standardization

Regulatory support and standardization are pivotal in shaping the Nucleic Acid Amplification Testing Market. Governments and health organizations are increasingly recognizing the importance of establishing clear guidelines for the use of nucleic acid tests. This regulatory framework not only ensures the safety and efficacy of testing methods but also fosters public trust in diagnostic technologies. As regulatory bodies streamline approval processes for new tests, the market is likely to experience accelerated growth. Moreover, standardization efforts contribute to the comparability of test results across different laboratories, enhancing the overall reliability of nucleic acid amplification tests. This supportive regulatory environment suggests a favorable outlook for the Nucleic Acid Amplification Testing Market.

Growing Demand for Personalized Medicine

The shift towards personalized medicine is significantly influencing the Nucleic Acid Amplification Testing Market. As healthcare moves towards tailored treatment plans based on individual genetic profiles, the need for precise diagnostic tools becomes paramount. Nucleic acid amplification tests facilitate the identification of specific genetic markers, enabling healthcare providers to customize therapies for patients. This trend is supported by an increasing number of clinical trials focusing on genetic testing, which is projected to drive market growth. The integration of these tests into routine clinical practice is likely to enhance patient outcomes and optimize resource allocation in healthcare systems. Consequently, the Nucleic Acid Amplification Testing Market is poised for expansion as it aligns with the evolving landscape of personalized healthcare.

Rising Prevalence of Infectious Diseases

The increasing incidence of infectious diseases is a primary driver for the Nucleic Acid Amplification Testing Market. As pathogens evolve and new strains emerge, the demand for rapid and accurate diagnostic tools intensifies. For instance, the World Health Organization has reported a rise in cases of diseases such as tuberculosis and hepatitis, necessitating advanced testing methods. Nucleic acid amplification tests provide high sensitivity and specificity, making them essential in clinical settings. The market is projected to grow as healthcare providers seek efficient solutions to manage outbreaks and ensure timely treatment. This trend indicates a robust future for the Nucleic Acid Amplification Testing Market, as it aligns with the urgent need for effective disease management strategies.

Technological Innovations in Testing Methods

Technological advancements play a crucial role in shaping the Nucleic Acid Amplification Testing Market. Innovations such as real-time PCR and next-generation sequencing have revolutionized the way nucleic acids are amplified and analyzed. These technologies enhance the speed and accuracy of diagnostics, allowing for quicker decision-making in clinical environments. The market is witnessing a surge in the adoption of automated systems that streamline testing processes, thereby reducing human error and increasing throughput. According to recent data, the market for automated nucleic acid amplification systems is expected to expand significantly, driven by the need for efficiency in laboratories. This evolution in technology suggests a promising trajectory for the Nucleic Acid Amplification Testing Market.

Increased Investment in Research and Development

Investment in research and development is a significant catalyst for the Nucleic Acid Amplification Testing Market. As stakeholders recognize the potential of nucleic acid tests in various applications, funding for innovative research is on the rise. This influx of capital supports the development of novel testing methodologies and enhances existing technologies. Furthermore, collaborations between academic institutions and industry players are fostering advancements in nucleic acid amplification techniques. The market is expected to benefit from these initiatives, as they lead to the introduction of more efficient and cost-effective testing solutions. This trend indicates a vibrant future for the Nucleic Acid Amplification Testing Market, driven by continuous innovation and improvement.

Market Segment Insights

By Technology: PCR (Largest) vs. RT-PCR (Fastest-Growing)

In the Nucleic Acid Amplification Testing Market, PCR (Polymerase Chain Reaction) technology dominates with a significant share due to its established reliability and widespread adoption in laboratories and diagnostic practices. In contrast, RT-PCR (Reverse Transcription PCR) has surged in popularity, primarily driven by its critical role in detecting RNA viruses and other pathogens swiftly and accurately, particularly during infectious disease outbreaks.

Technology: PCR (Dominant) vs. RT-PCR (Emerging)

PCR technology remains the cornerstone of nucleic acid amplification due to its effectiveness in various applications including disease diagnosis and genetic analysis. This method's ability to amplify specific DNA sequences has made it indispensable in clinical laboratories. On the other hand, RT-PCR is emerging as a crucial tool in molecular diagnostics, especially for the rapid testing of viral infections. Its adaptability and high sensitivity for RNA detection are propelling its growth, making it a vital technology in the ongoing battle against infectious diseases. Together, these technologies illustrate the dynamic evolution of the Nucleic Acid Amplification Testing Market.

By Application: Infectious Disease Testing (Largest) vs. Cancer Diagnosis (Fastest-Growing)

The Nucleic Acid Amplification Testing Market showcases a diverse range of applications, with Infectious Disease Testing occupying the largest share. It is crucial in rapidly diagnosing infections, thereby playing a pivotal role in managing public health crises. Following this, Cancer Diagnosis has emerged as the fastest-growing segment, reflecting the increasing prevalence of cancer and rising awareness about early detection and personalized medicine. This evolution underscores the market’s expansion and diversification. As we delve into growth trends, the surge in Infectious Disease Testing is primarily driven by advancements in testing technology and the growing incidences of infectious diseases globally. Conversely, Cancer Diagnosis is witnessing rapid growth due to significant investments in research and development, leading to innovative testing solutions. The rising adoption of Nucleic Acid Amplification Testing Market among healthcare providers also accentuates these trends, influencing how diseases are diagnosed and treated.

Infectious Disease Testing (Dominant) vs. Genetic Testing (Emerging)

Infectious Disease Testing stands as the dominant application in the Nucleic Acid Amplification Testing Market, crucial for swift and reliable diagnosis during outbreaks of various infectious diseases. This segment's strong market presence is attributed to its established protocols and continual advancements in test accuracy and speed. On the other hand, Genetic Testing is emerging rapidly, driven by a growing interest in personalized medicine and genetic research. Genetic Testing leverages nucleic acid amplification to identify genetic disorders, thereby catering to a specialized yet expanding customer base. As awareness rises about genetic conditions and the importance of early diagnosis, this segment is expected to flourish, introducing innovative testing methodologies that address diverse genetic profiles.

By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Nucleic Acid Amplification Testing Market, hospitals hold the largest market share, driven by their extensive capabilities in delivering a spectrum of diagnostic services. The increasing number of patients, coupled with the rising need for rapid and accurate diagnostic testing, solidifies the hospitals' position as leaders in this sector. Meanwhile, diagnostic laboratories are emerging swiftly, gaining considerable traction due to their specialized expertise and efficiency in conducting nucleic acid tests, leading to a significant share of the market. The growth trends within this segment exhibit a robust movement towards innovation and efficiency in testing procedures. Hospitals are increasingly investing in advanced technology to enhance their testing capabilities and reduce turnaround times. In contrast, diagnostic laboratories are capitalizing on the growing demand for point-of-care testing and personalized medicine, positioning themselves as key players in this rapidly evolving market. The combination of technological advancements and the growing prevalence of infectious diseases is fueling the expansion of both sectors within the nucleic acid testing landscape.

Hospitals (Dominant) vs. Research Institutes (Emerging)

Hospitals are recognized as the dominant players in the Nucleic Acid Amplification Testing Market, owing to their established infrastructure and regulatory support. They provide comprehensive diagnostic solutions, facilitating a wide array of tests that cover various medical conditions. Their reliance on nucleic acid amplification testing stems from the urgent need for quick and definitive results in patient care. In contrast, research institutes are emerging as vital contributors to the market, focusing on innovative research and development. Their role in advancing nucleic acid technologies places them at the forefront of scientific discovery, driving forward new methodologies that enhance test accuracy and speed. Both segments are vital in meeting the growing global demand for effective diagnostic solutions.

By Product Type: Reagents (Largest) vs. Instruments (Fastest-Growing)

The Nucleic Acid Amplification Testing Market is characterized by a diverse range of product types, prominently including 'Reagents', 'Instruments', 'Software', and 'Consumables'. Among these, Reagents hold the largest market share, reflecting their essential role in facilitating the amplification process. Meanwhile, Instruments represent the fastest-growing segment due to increasing technological advancements and the rising demand for high-throughput testing solutions that enhance accuracy and efficiency in nucleic acid testing.

Instruments (Dominant) vs. Software (Emerging)

Instruments are considered a dominant segment within the Nucleic Acid Amplification Testing Market, providing the necessary hardware for conducting amplification tests. These devices have advanced significantly, incorporating features that enable high throughput and precise results, thus making them vital in clinical laboratories and research settings. Conversely, Software is an emerging segment that complements the instrumentation by facilitating data analysis and result interpretation. As laboratories increasingly adopt automation and digital solutions, software tools are expected to become more integral, driving efficiencies in testing processes and enabling enhanced data management.

Get more detailed insights about Nucleic Acid Amplification Testing Market
Request Free Sample

Regional Insights

The Global Nucleic Acid Amplification Testing Market is poised for significant growth across various regions, with North America leading the charge as the dominant market, valued at 3.3 USD Billion in 2024 and projected to reach 8.7 USD Billion by 2035. This formidable presence is attributed to advanced healthcare infrastructure and a rise in infectious diseases. Europe follows closely, with a valuation of 2.2 USD Billion in 2024 and expected growth to 5.8 USD Billion by 2035, bolstered by the increasing adoption of personalized medicine and genomic testing.

The APAC region, valued at 1.5 USD Billion in 2024, shows promising growth potential, reaching 4.0 USD Billion by 2035, driven by the rising prevalence of chronic diseases and innovation in molecular diagnostics. Meanwhile, South America, although currently smaller at 0.7 USD Billion in 2024 and 1.8 USD Billion in 2035, reflects significant opportunities due to increasing healthcare investments. The MEA region marks 0.59 USD Billion in 2024 and anticipates growth to 1.9 USD Billion by 2035, influenced by improving healthcare access.

Together, these market segments collectively highlight the diverse landscape and growth potential of the Global Nucleic Acid Amplification Testing Market revenue.

Nucleic Acid Amplification Testing Market Regional Image

Key Players and Competitive Insights

The competitive landscape of the Global Nucleic Acid Amplification Testing Market is characterized by rapid advancements in technology, substantial investments in research and development, and an increasing demand for accurate and timely diagnostic solutions. The market is driven by a rising prevalence of infectious diseases, genetic disorders and the growing need for personalized medicine. As the importance of early detection and diagnosis continues to gain attention, key players are focusing on enhancing their product offerings and expanding their market presence through strategic partnerships, mergers, and acquisitions.This dynamic environment calls for companies to innovate consistently and adapt to changing regulatory guidelines while addressing the challenges posed by emerging market players and technological developments.Hologic has established a significant foothold in the Global Nucleic Acid Amplification Testing Market, known for its robust portfolio of molecular diagnostic products. The company leverages its advanced technology to offer reliable and efficient testing solutions, catering to a wide range of healthcare needs, including infectious disease detection and women's health. Hologic's innovative platforms and assays are designed to deliver rapid results, enhancing patient care and clinical decision-making. The company's commitment to continuous improvement and high-quality standards ensures that its products meet the stringent regulatory requirements in various regions.This strong emphasis on quality, combined with a strategic focus on expanding its market reach and enhancing customer relationships, positions Hologic as a formidable player in the competitive landscape of nucleic acid amplification testing.Abbott Laboratories is another key contender in the Global Nucleic Acid Amplification Testing Market, recognized for its extensive expertise in diagnostics and innovative solutions. With a diverse range of products that address both infectious diseases and genetic conditions, Abbott strives to provide rapid and accurate testing that aids in informed healthcare decisions. The company's dedication to research and development fosters a culture of innovation, enabling it to introduce cutting-edge technologies that meet the evolving needs of healthcare providers and patients alike. Abbott Laboratories also benefits from a well-established global distribution network, allowing it to reach diverse markets effectively.Through collaborations and partnerships, Abbott continues to enhance its product portfolio and maintain a competitive position in the nucleic acid amplification testing sector, dedicated to improving health outcomes worldwide.

Key Companies in the Nucleic Acid Amplification Testing Market include

Industry Developments

  • Q2 2024: Hologic Receives CE Mark for Panther Fusion SARS-CoV-2/Flu/RSV Assay Hologic announced it received CE marking for its Panther Fusion SARS-CoV-2/Flu/RSV assay, expanding its molecular diagnostic portfolio for respiratory viruses using nucleic acid amplification technology.
  • Q2 2024: QIAGEN launches QIAstat-Dx Analyzer 2.0 for syndromic testing QIAGEN launched the QIAstat-Dx Analyzer 2.0, a next-generation platform for syndromic testing using nucleic acid amplification, designed to deliver faster and more accurate results for infectious disease diagnostics.
  • Q2 2024: Roche launches new cobas 5800 molecular diagnostics system Roche announced the launch of its cobas 5800 system, a compact molecular diagnostics platform utilizing nucleic acid amplification for a broad range of infectious disease tests.
  • Q3 2024: Thermo Fisher Scientific Expands COVID-19 Testing Portfolio with New PCR Assay Thermo Fisher Scientific introduced a new PCR-based nucleic acid amplification assay for COVID-19, expanding its portfolio of molecular diagnostic solutions for infectious disease testing.
  • Q3 2024: Bio-Rad Laboratories Launches Droplet Digital PCR Assay for Oncology Applications Bio-Rad Laboratories launched a new droplet digital PCR assay for oncology, enabling highly sensitive nucleic acid amplification testing for cancer biomarkers.
  • Q3 2024: BD Receives FDA Clearance for BD MAX™ Respiratory Viral Panel BD announced FDA clearance for its BD MAX™ Respiratory Viral Panel, a multiplex nucleic acid amplification test for detecting multiple respiratory viruses in a single assay.
  • Q4 2024: Abbott launches Alinity m STI Assay for sexually transmitted infections Abbott launched the Alinity m STI Assay, a nucleic acid amplification test for simultaneous detection of multiple sexually transmitted infections, expanding its molecular diagnostics portfolio.
  • Q4 2024: Hologic Receives FDA Clearance for Aptima CMV Assay Hologic received FDA clearance for its Aptima CMV assay, a nucleic acid amplification test for cytomegalovirus, enhancing its offerings in transplant and immunocompromised patient diagnostics.
  • Q1 2025: Seegene partners with Siemens Healthineers for global distribution of molecular diagnostics Seegene announced a partnership with Siemens Healthineers to distribute its molecular diagnostic tests, including nucleic acid amplification assays, to expand global market reach.
  • Q1 2025: Illumina launches new NGS-based nucleic acid amplification test for rare disease diagnostics Illumina launched a new next-generation sequencing (NGS) based nucleic acid amplification test designed for the detection of rare genetic diseases, broadening its clinical genomics portfolio.
  • Q2 2025: bioMérieux receives FDA clearance for BIOFIRE® Pneumonia Panel bioMérieux received FDA clearance for its BIOFIRE® Pneumonia Panel, a multiplex nucleic acid amplification test for rapid identification of pneumonia pathogens.
  • Q2 2025: Danaher acquires molecular diagnostics firm Cepheid Danaher Corporation completed the acquisition of Cepheid, a leading provider of nucleic acid amplification testing platforms for infectious disease diagnostics.

Future Outlook

Nucleic Acid Amplification Testing Market Future Outlook

The Nucleic Acid Amplification Testing Market is projected to grow at a 9.19% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for rapid diagnostics, and rising prevalence of infectious diseases.

New opportunities lie in:

  • Development of portable testing devices for remote diagnostics
  • Integration of AI for enhanced data analysis and interpretation
  • Expansion into emerging markets with tailored testing solutions

By 2035, the nucleic acid amplification testing market is expected to be robust, driven by innovation and strategic expansions.

Market Segmentation

Nucleic Acid Amplification Testing Market End Use Outlook

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Home Care Settings

Nucleic Acid Amplification Testing Market Technology Outlook

  • PCR
  • LAMP
  • NASBA
  • RT-PCR

Nucleic Acid Amplification Testing Market Application Outlook

  • Infectious Disease Testing
  • Cancer Diagnosis
  • Genetic Testing
  • Transplant Diagnostics

Nucleic Acid Amplification Testing Market Product Type Outlook

  • Reagents
  • Instruments
  • Software
  • Consumables

Report Scope

MARKET SIZE 2024 7.294(USD Billion)
MARKET SIZE 2025 7.964(USD Billion)
MARKET SIZE 2035 19.19(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 9.19% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Qiagen (DE), Hologic (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Cepheid (US)
Segments Covered Technology, Applications, End Use, Product Type, Regional
Key Market Opportunities Advancements in point-of-care testing technologies enhance accessibility in the Nucleic Acid Amplification Testing Market.
Key Market Dynamics Technological advancements and regulatory changes drive growth in the Nucleic Acid Amplification Testing Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Nucleic Acid Amplification Testing Market by 2035?

The projected market valuation for the Nucleic Acid Amplification Testing Market by 2035 is 19.19 USD Billion.

What was the market valuation of the Nucleic Acid Amplification Testing Market in 2024?

The overall market valuation of the Nucleic Acid Amplification Testing Market was 7.294 USD Billion in 2024.

What is the expected CAGR for the Nucleic Acid Amplification Testing Market during the forecast period 2025 - 2035?

The expected CAGR for the Nucleic Acid Amplification Testing Market during the forecast period 2025 - 2035 is 9.19%.

Which technology segment is projected to have the highest valuation by 2035?

The PCR technology segment is projected to reach a valuation of 9.2 USD Billion by 2035.

What are the key applications driving growth in the Nucleic Acid Amplification Testing Market?

Key applications include Infectious Disease Testing, Cancer Diagnosis, Genetic Testing, and Transplant Diagnostics, with Infectious Disease Testing projected to reach 6.5 USD Billion by 2035.

Which companies are considered key players in the Nucleic Acid Amplification Testing Market?

Key players in the market include Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Qiagen, and Hologic.

What is the projected valuation for the Home Care Settings end-use segment by 2035?

The Home Care Settings end-use segment is projected to reach a valuation of 4.19 USD Billion by 2035.

How does the valuation of the Reagents product type segment compare to others by 2035?

The Reagents product type segment is projected to have the highest valuation at 6.5 USD Billion by 2035.

What is the expected growth trajectory for the Diagnostic Laboratories end-use segment?

The Diagnostic Laboratories end-use segment is expected to grow to a valuation of 5.0 USD Billion by 2035.

What role do companies like Cepheid play in the Nucleic Acid Amplification Testing Market?

Companies like Cepheid contribute to innovation and market leadership, enhancing the overall growth of the Nucleic Acid Amplification Testing Market.

Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Garvit Vyas LinkedIn
Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Get In Touch
Leave a Comment

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed scientific journals, clinical publications, epidemiological surveillance reports, and authoritative health organizations. Key sources included:

Regulatory & Government Authorities:

US Food and Drug Administration (FDA) – 510(k) clearances, PMA approvals, and emergency use authorizations for molecular diagnostic devices

Centers for Disease Control and Prevention (CDC) – infectious disease surveillance data, laboratory testing guidelines, and epidemiological statistics

National Institutes of Health (NIH) – research funding data and clinical trial registries

Centers for Medicare & Medicaid Services (CMS) – reimbursement codes and coverage policies for molecular diagnostics

Biomedical Advanced Research and Development Authority (BARDA) – funding initiatives for diagnostic preparedness

European Medicines Agency (EMA) – CE-IVD certifications and regulatory pathways

European Centre for Disease Prevention and Control (ECDC) – disease burden statistics and testing recommendations

European Commission Health and Food Safety Directorate (DG SANTE) – diagnostic regulatory frameworks

UK Health Security Agency (UKHSA) – national screening program data and infectious disease monitoring

Health Canada – medical device licenses and diagnostic regulations

Therapeutic Goods Administration (TGA) – Australian regulatory approvals

Pharmaceuticals and Medical Devices Agency (PMDA) – Japanese medical device approvals

China National Medical Products Administration (NMPA) – domestic IVD registrations

Indian Council of Medical Research (ICMR) – national laboratory surveillance networks

World Health Organization (WHO) – Global Health Observatory, Essential Diagnostics List, and international testing guidelines

Professional & Industry Organizations:

Association for Molecular Pathology (AMP) – professional practice guidelines and market trends

American Association for Clinical Chemistry (AACC) – laboratory medicine standards

Clinical and Laboratory Standards Institute (CLSI) – quality control and testing protocols

Infectious Diseases Society of America (IDSA) – clinical practice guidelines

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) – diagnostic recommendations

International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) – global laboratory standards

American Society for Microbiology (ASM) – pathogen detection methodologies

National Center for Biotechnology Information (NCBI/PubMed) – peer-reviewed research on PCR, isothermal amplification, and next-generation diagnostic technologies

Commercial & Market Intelligence Sources:

Global Industry Analysts, Grand View Research, Frost & Sullivan, and BCC Research for competitive benchmarking

Company annual reports, SEC filings (10-K, 10-Q), investor presentations, and press releases from key manufacturers

Patent databases (USPTO, EPO, WIPO) for technology innovation tracking

These sources were utilized to collect epidemiological data, regulatory approval timelines, clinical sensitivity/specificity studies, testing volume statistics, reimbursement landscapes, and competitive intelligence for PCR-based, isothermal amplification (LAMP, NASBA, TMA), and transcription-mediated amplification (TMA) technologies across infectious disease, oncology, genetic testing, and blood screening applications.

Primary Research

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of R&D, regulatory affairs directors, commercial heads, and business development executives from IVD firms, reagent suppliers, and molecular diagnostic manufacturers were examples of supply-side sources. Laboratory directors, clinical microbiologists, molecular pathologists, infectious disease experts, hospital administrators, and procurement officers from academic medical institutions, reference laboratories, hospital networks, and public health laboratories were examples of demand-side sources. Primary research verified product pipeline timelines, gathered information on automation trends, point-of-care adoption, pricing pressures, and regulatory compliance requirements, and validated market segmentation by technology (PCR, isothermal amplification, strand displacement amplification), application (infectious disease, oncology, genetic disorders, blood screening), and end-user (hospitals, diagnostic laboratories, blood banks, research institutions).

Primary Respondent Breakdown:

Table

Copy

Category Segmentation Percentage

By Company Tier Tier 1 (>$5B revenue) 38%

Tier 2 ($500M-$5B) 31%

By Designation C-level Primaries 32%

Director Level 34%

Others (Managers, Scientists, Lab Heads) 34%

By Region North America 32%

Europe 29%

Asia-Pacific 28%

Rest of World (Latin America, MEA) 11%

Market Size Estimation

Global market valuation was derived through revenue mapping and testing volume analysis. The methodology included:

Identification of 55+ key manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Technology mapping across PCR-based, isothermal amplification (LAMP, NASBA, SDA, TMA), transcription-mediated amplification, and next-generation digital PCR platforms

Application segmentation covering infectious disease (COVID-19, HIV, hepatitis, TB, respiratory panels), oncology (liquid biopsy, companion diagnostics), genetic testing, and blood screening

Analysis of reported and modeled annual revenues specific to NAAT product portfolios, including instruments, reagents, and software/services

Coverage of manufacturers representing 65-70% of global market share in 2024

Extrapolation using bottom-up approach (test volume × ASP by country/region, adjusted for test menu complexity and automation level) and top-down approach (manufacturer revenue validation, market share modeling) to derive segment-specific valuations

Triangulation with epidemiological disease burden data and testing frequency guidelines to validate demand-side estimates

This methodology ensures robust, defensible market sizing with comprehensive coverage of the nucleic acid amplification testing ecosystem across clinical diagnostics, research, and public health surveillance applications.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035